NCT07033000

Brief Summary

Randomized, Double-Blind, Placebo-Controlled, Single-Center Clinical Study, where participants will take the Daily Supplement, and record Daily Symptoms, two clinical visits where Hydrogen and Methane Breath Test (HMBT) will be conducted, Abdominal Circumference Measurement will be taken, and two Self Reported Validated Questionnaires: Visual Analogue Scale (VAS) and the Quality of Life Questionnaires.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P50-P75 for not_applicable healthy

Timeline
Completed

Started Jul 2025

Shorter than P25 for not_applicable healthy

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 13, 2025

Completed
11 days until next milestone

First Posted

Study publicly available on registry

June 24, 2025

Completed
20 days until next milestone

Study Start

First participant enrolled

July 14, 2025

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 25, 2025

Completed
21 days until next milestone

Study Completion

Last participant's last visit for all outcomes

September 15, 2025

Completed
Last Updated

June 24, 2025

Status Verified

June 1, 2025

Enrollment Period

1 month

First QC Date

June 13, 2025

Last Update Submit

June 13, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • To determine the impact of BTB on hydrogen and methane production in healthy adults

    Participants will take the Hydrogen and Methane Breath Test (HMBT) at baseline and after the study at Week4.

    From time of enrollement to end of study at Week4

Secondary Outcomes (2)

  • To estimate the changes in abdominal circumference as an indicator of distention

    From time of enrollement to end of study at Week4

  • To assess the changes in validated subjective questionnaire (VAS) for bloating, abdominal pain, distension, and flatulence.

    From time of enrollement to end of study at Week4

Study Arms (2)

Placebo

PLACEBO COMPARATOR

Oral dietary supplement. Instructions: Take 1 capsule with water as needed, up to 3 capsules per day. Do not take more than 3.

Dietary Supplement: Placebo

Dietary Supplement with actives

ACTIVE COMPARATOR

Oral dietary supplement. Instructions: Take 1 capsule with water as needed, up to 3 capsules per day. Do not take more than 3.

Dietary Supplement: Dietary Supplement with actives

Interventions

PlaceboDIETARY_SUPPLEMENT

Placebo

Placebo

Dietary Supplement containing blend of Digestive Enzymes, Dandelion, Ginger \& Fennel Extracts

Dietary Supplement with actives

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Healthy Adults aged 18-65 years
  • Reported bloating and/or distention occurring at least once per week for the past 6 months, with symptoms actively present during the past 3 months
  • Willingness to avoid probiotics, antibiotics, or other supplements during the study period (unless approved by investigators)
  • Ability to provide informed consent and comply with all protocol requirements

You may not qualify if:

  • Diagnosed gastrointestinal diseases (e.g., inflammatory bowel disease, celiac disease, GI malignancies)
  • Use of antibiotics, laxatives, or probiotics within the past 4 weeks
  • Uncontrolled diabetes mellitus
  • Presence of mood disorders or psychiatric illness that may affect symptom perception or study compliance
  • Immunodeficiency, autoimmune conditions, or chronic inflammatory conditions
  • Excessive alcohol intake (\>14 drinks/week for men, \>7 drinks/week for women)
  • Use of medications known to affect gut motility or gas production (e.g., opioids, anticholinergics)
  • Pregnant or breastfeeding women
  • Use of systemic corticosteroids or immunosuppressant drugs.
  • History of reaction to the category of product tested
  • Other diseases or medications that might directly interfere in the study or put the subject's health under risk.
  • Employee of CRO or product manufacturer

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

MusB Research

New Port Richey, Florida, 34653, United States

Location

MeSH Terms

Interventions

Dietary Supplements

Intervention Hierarchy (Ancestors)

FoodDiet, Food, and NutritionPhysiological PhenomenaFood and Beverages

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, CARE PROVIDER
Purpose
SUPPORTIVE CARE
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 13, 2025

First Posted

June 24, 2025

Study Start

July 14, 2025

Primary Completion

August 25, 2025

Study Completion

September 15, 2025

Last Updated

June 24, 2025

Record last verified: 2025-06

Locations